A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Summary

The purpose of this trial is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of GEN3017 as a monotherapy in participants with relapsed or refractory (R/R) CD30-expressing lymphomas. GEN3017 will be administered via subcutaneous injections. All participants will receive active drug; no one will be given placebo.

Timeline

Start

2023-09-21

Primary completion

2025-02-05

Completion

2025-02-05

Outcome

Outcome not reported

Stopped (Business): “Genmab discontinued GEN3017 program following a strategic re-evaluation of Genmab's portfolio.”

Drugs

Indications